<?xml version='1.0' encoding='utf-8'?>
<document id="22271159"><sentence text="Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin."><entity charOffset="45-58" id="DDI-PubMed.22271159.s1.e0" text="dapagliflozin" /><entity charOffset="63-74" id="DDI-PubMed.22271159.s1.e1" text="simvastatin" /><entity charOffset="76-85" id="DDI-PubMed.22271159.s1.e2" text="valsartan" /><entity charOffset="87-95" id="DDI-PubMed.22271159.s1.e3" text="warfarin" /><entity charOffset="100-107" id="DDI-PubMed.22271159.s1.e4" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e0" e2="DDI-PubMed.22271159.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e0" e2="DDI-PubMed.22271159.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e0" e2="DDI-PubMed.22271159.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e0" e2="DDI-PubMed.22271159.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e0" e2="DDI-PubMed.22271159.s1.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e1" e2="DDI-PubMed.22271159.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e1" e2="DDI-PubMed.22271159.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e1" e2="DDI-PubMed.22271159.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e1" e2="DDI-PubMed.22271159.s1.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e2" e2="DDI-PubMed.22271159.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e2" e2="DDI-PubMed.22271159.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e2" e2="DDI-PubMed.22271159.s1.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e3" e2="DDI-PubMed.22271159.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s1.e3" e2="DDI-PubMed.22271159.s1.e4" /></sentence><sentence text="Coronary heart disease, stroke, and peripheral vascular disease are the most common causes of mortality in patients with type 2 diabetes mellitus (T2DM)" /><sentence text=" The aim of these studies was to assess the potential for pharmacokinetic interaction between dapagliflozin, a sodium glucose co-transporter-2 inhibitor being developed for the treatment of T2DM, and four medications commonly prescribed in patients with T2DM and cardiovascular disease: simvastatin, valsartan, warfarin, and digoxin"><entity charOffset="94-107" id="DDI-PubMed.22271159.s3.e0" text="dapagliflozin" /><entity charOffset="111-125" id="DDI-PubMed.22271159.s3.e1" text="sodium glucose" /><entity charOffset="287-298" id="DDI-PubMed.22271159.s3.e2" text="simvastatin" /><entity charOffset="300-309" id="DDI-PubMed.22271159.s3.e3" text="valsartan" /><entity charOffset="311-319" id="DDI-PubMed.22271159.s3.e4" text="warfarin" /><entity charOffset="325-332" id="DDI-PubMed.22271159.s3.e5" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e0" e2="DDI-PubMed.22271159.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e0" e2="DDI-PubMed.22271159.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e0" e2="DDI-PubMed.22271159.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e0" e2="DDI-PubMed.22271159.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e0" e2="DDI-PubMed.22271159.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e0" e2="DDI-PubMed.22271159.s3.e5" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e1" e2="DDI-PubMed.22271159.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e1" e2="DDI-PubMed.22271159.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e1" e2="DDI-PubMed.22271159.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e1" e2="DDI-PubMed.22271159.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e1" e2="DDI-PubMed.22271159.s3.e5" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e2" e2="DDI-PubMed.22271159.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e2" e2="DDI-PubMed.22271159.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e2" e2="DDI-PubMed.22271159.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e2" e2="DDI-PubMed.22271159.s3.e5" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e3" e2="DDI-PubMed.22271159.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e3" e2="DDI-PubMed.22271159.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e3" e2="DDI-PubMed.22271159.s3.e5" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e4" e2="DDI-PubMed.22271159.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s3.e4" e2="DDI-PubMed.22271159.s3.e5" /></sentence><sentence text="" /><sentence text="Potential pharmacokinetic interactions between 20 mg dapagliflozin, 40 mg simvastatin, or 320 mg valsartan were assessed in an open-label, randomized, five-period, five-treatment, unbalanced crossover study in 24 healthy subjects"><entity charOffset="53-66" id="DDI-PubMed.22271159.s5.e0" text="dapagliflozin" /><entity charOffset="74-85" id="DDI-PubMed.22271159.s5.e1" text="simvastatin" /><entity charOffset="97-106" id="DDI-PubMed.22271159.s5.e2" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.22271159.s5.e0" e2="DDI-PubMed.22271159.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s5.e0" e2="DDI-PubMed.22271159.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s5.e0" e2="DDI-PubMed.22271159.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s5.e1" e2="DDI-PubMed.22271159.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s5.e1" e2="DDI-PubMed.22271159.s5.e2" /></sentence><sentence text=" In a second study, the effects of steady-state dapagliflozin on the pharmacokinetics of 25 mg warfarin or 0"><entity charOffset="48-61" id="DDI-PubMed.22271159.s6.e0" text="dapagliflozin" /><entity charOffset="95-103" id="DDI-PubMed.22271159.s6.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.22271159.s6.e0" e2="DDI-PubMed.22271159.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s6.e0" e2="DDI-PubMed.22271159.s6.e1" /></sentence><sentence text="25 mg digoxin were assessed in an open-label, randomized, two-period, two-treatment crossover study in 30 healthy subjects divided into two cohorts"><entity charOffset="6-13" id="DDI-PubMed.22271159.s7.e0" text="digoxin" /></sentence><sentence text=" The potential pharmacodynamic interaction between dapagliflozin and warfarin was also evaluated"><entity charOffset="51-64" id="DDI-PubMed.22271159.s8.e0" text="dapagliflozin" /><entity charOffset="69-77" id="DDI-PubMed.22271159.s8.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.22271159.s8.e0" e2="DDI-PubMed.22271159.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s8.e0" e2="DDI-PubMed.22271159.s8.e1" /></sentence><sentence text="" /><sentence text="All treatments were well tolerated" /><sentence text=" Neither simvastatin nor valsartan had any clinically meaningful effect on the pharmacokinetics of dapagliflozin"><entity charOffset="9-20" id="DDI-PubMed.22271159.s11.e0" text="simvastatin" /><entity charOffset="25-34" id="DDI-PubMed.22271159.s11.e1" text="valsartan" /><entity charOffset="99-112" id="DDI-PubMed.22271159.s11.e2" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.22271159.s11.e0" e2="DDI-PubMed.22271159.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s11.e0" e2="DDI-PubMed.22271159.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s11.e0" e2="DDI-PubMed.22271159.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s11.e1" e2="DDI-PubMed.22271159.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s11.e1" e2="DDI-PubMed.22271159.s11.e2" /></sentence><sentence text=" Dapagliflozin increased the area under the curve for simvastatin, simvastatin acid, and valsartan by approximately 19%, 30%, and 6%, respectively, and decreased the maximum observed plasma concentration of valsartan by approximately 6%"><entity charOffset="1-14" id="DDI-PubMed.22271159.s12.e0" text="Dapagliflozin" /><entity charOffset="54-65" id="DDI-PubMed.22271159.s12.e1" text="simvastatin" /><entity charOffset="67-83" id="DDI-PubMed.22271159.s12.e2" text="simvastatin acid" /><entity charOffset="89-98" id="DDI-PubMed.22271159.s12.e3" text="valsartan" /><entity charOffset="207-216" id="DDI-PubMed.22271159.s12.e4" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e0" e2="DDI-PubMed.22271159.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e0" e2="DDI-PubMed.22271159.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e0" e2="DDI-PubMed.22271159.s12.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e0" e2="DDI-PubMed.22271159.s12.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e0" e2="DDI-PubMed.22271159.s12.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e1" e2="DDI-PubMed.22271159.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e1" e2="DDI-PubMed.22271159.s12.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e1" e2="DDI-PubMed.22271159.s12.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e1" e2="DDI-PubMed.22271159.s12.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e2" e2="DDI-PubMed.22271159.s12.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e2" e2="DDI-PubMed.22271159.s12.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e2" e2="DDI-PubMed.22271159.s12.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e3" e2="DDI-PubMed.22271159.s12.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s12.e3" e2="DDI-PubMed.22271159.s12.e4" /></sentence><sentence text=" These effects were not considered clinically meaningful" /><sentence text=" In addition, dapagliflozin had no effect on the pharmacokinetics of either digoxin or warfarin"><entity charOffset="14-27" id="DDI-PubMed.22271159.s14.e0" text="dapagliflozin" /><entity charOffset="76-83" id="DDI-PubMed.22271159.s14.e1" text="digoxin" /><entity charOffset="87-95" id="DDI-PubMed.22271159.s14.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.22271159.s14.e0" e2="DDI-PubMed.22271159.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s14.e0" e2="DDI-PubMed.22271159.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s14.e0" e2="DDI-PubMed.22271159.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s14.e1" e2="DDI-PubMed.22271159.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s14.e1" e2="DDI-PubMed.22271159.s14.e2" /></sentence><sentence text=" The pharmacodynamics of warfarin were also unaffected by dapagliflozin"><entity charOffset="58-71" id="DDI-PubMed.22271159.s15.e0" text="dapagliflozin" /></sentence><sentence text="" /><sentence text="In these studies the co-administration of dapagliflozin and simvastatin, valsartan, warfarin, or digoxin was well tolerated without clinically meaningful drug-drug interaction"><entity charOffset="42-55" id="DDI-PubMed.22271159.s17.e0" text="dapagliflozin" /><entity charOffset="60-71" id="DDI-PubMed.22271159.s17.e1" text="simvastatin" /><entity charOffset="73-82" id="DDI-PubMed.22271159.s17.e2" text="valsartan" /><entity charOffset="84-92" id="DDI-PubMed.22271159.s17.e3" text="warfarin" /><entity charOffset="97-104" id="DDI-PubMed.22271159.s17.e4" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e0" e2="DDI-PubMed.22271159.s17.e0" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e0" e2="DDI-PubMed.22271159.s17.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e0" e2="DDI-PubMed.22271159.s17.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e0" e2="DDI-PubMed.22271159.s17.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e0" e2="DDI-PubMed.22271159.s17.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e1" e2="DDI-PubMed.22271159.s17.e1" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e1" e2="DDI-PubMed.22271159.s17.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e1" e2="DDI-PubMed.22271159.s17.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e1" e2="DDI-PubMed.22271159.s17.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e2" e2="DDI-PubMed.22271159.s17.e2" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e2" e2="DDI-PubMed.22271159.s17.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e2" e2="DDI-PubMed.22271159.s17.e4" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e3" e2="DDI-PubMed.22271159.s17.e3" /><pair ddi="false" e1="DDI-PubMed.22271159.s17.e3" e2="DDI-PubMed.22271159.s17.e4" /></sentence><sentence text="" /></document>